AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (previously presented) A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of general formulae I and Ia below for treating, by virtue of their cytotoxic properties, cancerous tumors and their metastases:



Formula I



Formula Ia

in which:

- X is chosen from oxygen,
- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,
- R_2 is chosen from hydrogen and halogens,
- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and

groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ groups and n = 1 to 3,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5, R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkyl, -CHO, -COOH, -CN, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, -phenyl-CO-CH_3 and $-CH_2-CH_2-N(CH_3)_2$ groups,

-phenyl-CO-CH_3 or -phenyl-CO-CH=CH-$N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

and the addition salts of these compounds with pharmaceutically acceptable acids.

2. (previously presented) A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of formula I in which:

- X is chosen from oxygen,

- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_2 is chosen from hydrogen and halogens,

- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl, $-(CH_2)_2-N(CH_3)_2$, and $-(CH_2)_2-O-(CH_2)_2-N(CH_3)_2$ groups,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5, R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, -CHO, -COOH, -CN, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ groups in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl and $-CH_2-CH_2-N(CH_3)_2$ groups,

-phenyl-$CO-CH_3$ or -phenyl-$CO-CH=CH-N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

and the addition salts of these compounds are with pharmaceutically acceptable acids.

3. (previously presented) The pharmaceutical composition as claimed in claim 2, comprising an effective amount of a compound chosen from the compounds of formula I in which:

- X represents oxygen,
- R_1 is chosen from hydrogen and an amino group,
- R_2 is chosen from hydrogen and halogens,
- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, methyl groups, (C_1-C_4) phenylalkyl, $-(CH_2)_2-N(CH_3)_2$, $-(CH_2)_2-O-(CH_2)_2-N(CH_3)_2$ groups,
- R_4 is chosen from hydrogen, halogens and nitro and amino groups,
- R_5, R_6 and R_7 represent a hydrogen,

and the addition salts of these compounds with pharmaceutically acceptable acids.

4. (previously presented) The pharmaceutical composition as claimed in claim 1, comprising an effective amount

of a compound chosen from the compounds of formulae I and Ia in which:

- X represents oxygen,
- R_1 is chosen from hydrogen and an amino group,
- R_2 is chosen from hydrogen and halogens,
- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, methyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and groups CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ and n = 1 to 3,
- R_4 is chosen from hydrogen, halogens, and nitro and amino groups,
- R_5 is chosen from a hydrogen, a halogen and a methoxy group,
- R_6 and R_7 are chosen from hydrogen and C_1-C_6 alkoxy, (C_1-C_6)alkoxy(C_1-C_6)alkyl and $-CH_2OCOCH_3$ groups,

and the addition salts of these compounds with pharmaceutically acceptable acids.

5. (previously presented) The composition as claimed in claim 4, in which the compounds are chosen from:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]-phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

and the addition salts thereof with pharmaceutically acceptable acids.

6. (cancelled)

7. (previously presented) The process according to claim 12, wherein said compound is selected from the group consisting of:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]-phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

and the addition salts thereof with pharmaceutically acceptable acids.

8. (previously presented) Compounds of general formulae I and Ia



Formula I



Formula Ia

in which:

- X is chosen from oxygen,
- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,
- R_2 is chosen from hydrogen and halogens,
- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being

chosen from halogens and CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ groups and n = 1 to 3,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5, R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkyl, -CHO, -COOH, -CN, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, -phenyl-CO-CH_3 and $-CH_2-CH_2-N(CH_3)_2$ groups,

-phenyl-CO-CH_3 or -phenyl-CO-CH=CH-$N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

and the addition salts of these compounds with pharmaceutically acceptable acids.

9. (previously presented) Compounds as claimed in claim 8, of formula I in which:

- X is chosen from oxygen,

- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_2 is chosen from hydrogen and halogens,

- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl, $-(CH_2)_2-N(CH_3)_2$, and $-(CH_2)_2-O-(CH_2)_2-N(CH_3)_2$ groups,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5, R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, -CHO, -COOH, -CN, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl and $-CH_2-CH_2-N(CH_3)_2$ groups,

-phenyl-$CO-CH_3$ or -phenyl-$CO-CH=CH-N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

and the addition salts thereof with pharmaceutically acceptable acids.

10. (previously presented) Compounds as claimed in claim 8, which are:

5-(dimethylamino)-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-(benzylamino)-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-bromo-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-methyl-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-chloro-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9*H*-quino[4,3,2-*de*][1,10]-phenanthrolin-9-one,

5-bis(2-chloroethyl)amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-(2-chloroethyl)amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

4-bromo-5-amino-9-*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

5-bromo-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one,

5-amino-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one,

5-bis(chloroethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one,

5-(chloroethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one,

4-bromo-5-amino-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one,

and the addition salts thereof with pharmaceutically acceptable acids.

11. (previously presented) A process for preparing a compound of formula Ia, in which:

- X is chosen from oxygen,
- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,
- R_2 is chosen from hydrogen and halogens,
- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ groups and n = 1 to 3,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5, R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkyl, -CHO, -COOH, -CN, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, -phenyl-CO-CH_3 and $-CH_2-CH_2-N(CH_3)_2$ groups,

-phenyl-CO-CH_3 or -phenyl-CO-CH=CH-$N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

which consists in:

a - condensing a chlorobenzoic acid of formula:



with a dimethoxyaniline of formula:



to give a compound of formula IIa:



b - cyclizing the compound of formula IIa to give a compound of formula:



c - converting the compound into a quinone of formula IIIa:



d - reacting the quinone of formula IIIa with an azadiene of formula:



to give a compound of formula IVa:



e - reacting the compound of the formula IVa with dimethylformamide diethyl acetal to give the compound of formula Ia,

f - and, optionally, converting the compound thus obtained into another compound of formula Ia.

12. (currently amended) A ~~process for~~ method of inhibiting the growth of a cancerous tumor in a patient, wherein said tumor is selected from the group consisting of breast cancer, prostate cancer, lung cancer, colorectal cancer, bladder cancer, glioblastomas, and astrocytomas ~~comprising administering an effective amount of a compound as defined in claim 1 to said patient~~.

13. (previously presented) A process for preparing compounds of general formula I, of formula:



in which:

- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_2 is chosen from hydrogen and halogens,

- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ groups and $-N(CH_3)_2$ and n = 1 to 3,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5, R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkyl,

-CHO, -COOH, -CN, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, -phenyl-CO-CH_3 and $-CH_2-CH_2-N(CH_3)_2$ groups,

-phenyl-CO-CH_3 or -phenyl-CO-CH=CH-$N(CH_3)_2$,

morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

with the exclusion of the compounds of formula I in which R_1, R_2, R_4, R_5, R_6, R_7 = H and R_3 = OCH_3, which consists

a) in reacting a hydroquinone of formula



with a compound of formula



in the presence of $CeCl_3$, $7H_2O$ and ethanol to give a compound of formula II



b) in converting the compound of formula II into a compound of formula III in the presence of H_2SO_4 in reflux acetic acid,



c) in reacting the compound of the formula III with $HC(OC_2H_5)_2N(CH_3)_2$ in DMF at 120°C to form a compound of formula IV



d) in cyclizing the compound of formula IV to a compound of formula I in the presence of NH_4Cl and AcOH,

e) optionally converting the compound of formula I thus obtained into another compound of formula II.

14. (previously presented) A compound of formula



in which:

- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,
- R_2 is chosen from hydrogen and halogens,

- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ groups and n = 1 to 3,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5, R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_1-C_4)alkylcarbonyloxy(C_1-C_4)alkyl, -CHO, -COOH, -CN, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, -phenyl-$CO-CH_3$ and $-CH_2-CH_2-N(CH_3)_2$ groups,

-phenyl-$CO-CH_3$ or -phenyl-$CO-CH=CH-N(CH_3)_2$,

morpholino, nitro or SO_3H groups,

groups:



,



,

R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

with the exclusion of compounds in which R_1, R_2, R_4, R_5, R_6, R_7 = H and R_3 = OCH_3,

and the addition salts of these compounds with pharmaceutically acceptable acids.

15. (new) A method of inhibiting the growth of a cancerous tumor in a patient, wherein said tumor is selected from the group consisting of breast cancer, prostate cancer, non-small-cell lung cancer, colorectal cancer, bladder cancer, glioblastomas, and astrocytomas.

16. (new) The process according to claim 15, wherein said compound is selected from the group consisting of:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]-phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

and the addition salts thereof with pharmaceutically acceptable acids.